UK Biobank Whole Genome Sequencing project
Together with deCODE in Iceland, the Sanger Institute has read and assembled the whole genome sequences of 500,000 UK Biobank volunteers. The Sanger Institute sequenced 243,633 whole human genomes.
This was one of the most ambitious sequencing efforts of whole human genomes ever undertaken. Sequencing took place over 27 months, starting in September 2019. It built on the ongoing success of the pilot programme, known as the Vanguard project, in which Sanger sequenced 10 per cent of the cohort – 50,000 genomes of UK Biobank volunteers.
A dataset of this magnitude will be incredibly powerful for understanding the genetic architecture that contributes to diseases such as cancer, cardiovascular diseases, depression and dementia.
The £200m project was funded by a collaboration between the government’s research and innovation agency, UK Research and Innovation (UKRI), Wellcome, Amgen, AstraZeneca, GlaxoSmithKline (GSK) and Johnson & Johnson*.
The first 200,000 UK Biobank participants were made available to researchers through the Research Analysis Platform.
The expectation is that sequence data for the entire cohort of UK Biobank participants will be generally accessible in 2023.
* Contract entered by Janssen Biotech Inc., one of the Pharmaceutical Companies of Johnson & Johnson; collaboration facilitated by the Johnson & Johnson EMEA Innovation center in London, UK
Contact
If you need help or have any queries, please contact us at: contact@sanger.ac.uk
Related News and Blogs
Our UK Biobank Journey: 3 years and over 240,000 human genomes
In 2019, the Sanger Institute started work on the most ambitious human genome sequencing project in the world. Three years later, the Institute has delivered nearly 250,000 whole human genome sequences and over 20 petabytes (PB) of data for the UK Biobank project, to aid research into health and disease… Read more
Powering discovery in blood disorders and depression
The wealth of information available to researchers through UK Biobank is powering studies into human health and disease… Read more
Sanger people
Dr Cordelia Langford
Director of Scientific Operations
External partners and funders
External
deCODE genetics
External
UK Research and Innovation (UKRI)
External
Wellcome
External
Amgen
External
AstraZeneca
External
GlaxoSmithKline (GSK)
External
Johnson and Johnson
External
Illumina
Related groups
Programmes and Facilities
Affiliated Sites
External